Coeptis Therapeutics Inc. (OTCPK:COEP) agreed to acquire TLR5 Immunity Receptor Agnonist Platform from Statera Biopharma, Inc. (NasdaqCM:STAB) for $6 million on April 6, 2022. The consummation of the transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a financing contingency.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.299 USD | +2.68% |
|
+6.41% | -61.86% |
Jun. 17 | Ladenburg Downgrades Coeptis Therapeutics to Neutral From Buy | MT |
Jun. 14 | Coeptis Therapeutics Holdings, Inc. announced that it has received $4.3 million in funding | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
0.299 USD | +2.68% | +6.41% | 10.81M | ||
0.0006 USD | 0.00% | 0.00% | 43.55K | ||
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.86% | 10.81M | |
+62.66% | 841B | |
+40.42% | 625B | |
-4.37% | 360B | |
+17.16% | 327B | |
+9.87% | 300B | |
+15.66% | 242B | |
+17.90% | 227B | |
+14.86% | 174B | |
+0.45% | 162B |
- Stock Market
- Equities
- COEP Stock
- News Coeptis Therapeutics Holdings, Inc.
- Coeptis Therapeutics Inc. agreed to acquire TLR5 Immunity Receptor Agnonist Platform from Statera Biopharma, Inc. for $6 million.